Disease course of Chronic Relapsing Inflammatory Optic Neuropathy (CRION) in a single care center / Evolución de la enfermedad de la neuropatía óptica inflamatoria crónica recidivante (CRION) en un solo centro de atención

ABSTRACT Background: Chronic relapsing inflammatory optic neuropathy (CRION) is a recurrent, idiopathic optic neuritis and is considered as a rare disease. Objective: To describe the clinical course during long-term follow-up of patients with a diagnosis of CRION. Methods: From a cohort of 1,735 patients with demyelinating disorders, we selected patients aged over 16 years with CRION according to current criteria. Demographic and clinical data, including initial presentation, symptoms, number of relapses, time delay in diagnosis, diagnostic methods, and treatment were obtained from clinical files. Infections, autoimmune diseases, and multiple sclerosis, among other conditions, were ruled out in all patients. Results: We analyzed 30 patients with CRION: 24 women and six men, with mean age of 42.8±10.2 years, median disease course of 7.9 years (5.29-13.1), and median number of attacks of 2 (IQR 2-4). The initial manifestation was ocular pain in 97% and bilateral and sequential affection in 87%. Visual acuity was recovered in 50%, did not improve in 33%, and recovered incompletely in 17%. Antibodies against aquaporin-4 (AQP4-Abs) were negative in 73.3%. Magnetic resonance imaging of the brain was normal in 76.7%. None of the patients evolved to another demyelinating disease over time. Initial treatment was methylprednisolone in 100%, and plasmapheresis in 20%. Currently, all patients are on maintenance treatment with mycophenolate mofetil or rituximab with a decrease in relapsing rate. Conclusions: Diagnosis of CRION is challenging and should be kept in mind. Prompt diagnosis, adequate treatment and close follow-up are essential to prevent disabling sequelae in these patients.

RESUMEN Antecedentes: Neuropatía óptica inflamatoria crónica recidivante (CRION) es una neuritis óptica idiopática recurrente, considerada una enfermedad rara. Objetivo: Describir la evolución clínica durante el seguimiento a largo plazo de pacientes con diagnóstico de CRION. Métodos: De una cohorte de 1.735 pacientes con trastornos desmielinizantes, seleccionamos pacientes mayores de 16 años con diagnóstico de CRION según los criterios actuales. Datos demográficos y clínicos, incluyendo presentación inicial, síntomas, recaídas, tiempo de retraso diagnóstico, métodos de diagnóstico y tratamiento se obtuvieron de los archivos clínicos. Se descartaron en todos los pacientes infecciones, enfermedades autoinmunes, esclerosis múltiple, entre otras condiciones. Resultados: Se analizaron 30 pacientes con diagnóstico de CRION: 24 mujeres y 6 hombres, edad media de 42,8±10,2 años, mediana del curso de la enfermedad de 7,9 años (5,2-13,1), mediana del número de recaídas 2 (IQR 2-4). La manifestación inicial fue dolor ocular en el 97% y afección bilateral y secuencial en el 87%. La agudeza visual mejoró en el 50%, sin recuperación en el 33% y con restauración incompleta en el 17%. Los anticuerpos contra acuaporina-4 (AQP4-Abs) fueron negativos en el 73,3%. La resonancia magnética cerebral fue normal en el 76,7%. Ningún paciente evolucionó hacia otra enfermedad desmielinizante en el seguimiento. El tratamiento inicial fue metilprednisolona en el 100%, y plasmaféresis en el 20%. Actualmente, todos los pacientes están en tratamiento de mantenimiento con micofenolato de mofetilo o rituximab con disminución de la tasa de recaídas. Conclusiones: El diagnóstico de CRION representa un desafío y debe tenerse en cuenta. El diagnóstico oportuno, tratamiento adecuado y seguimiento estrecho son fundamentales para evitar secuelas invalidantes.

Disease course of Chronic Relapsing Inflammatory Optic Neuropathy (CRION) in a single care center.

BACKGROUND: Chronic relapsing inflammatory optic neuropathy (CRION) is a recurrent, idiopathic optic neuritis and is considered as a rare disease. OBJECTIVE: To describe the clinical course during long-term follow-up of patients with a diagnosis of CRION. METHODS: From a cohort of 1,735 patients with demyelinating disorders, we selected patients aged over 16 years with CRION according to current criteria. Demographic and clinical data, including initial presentation, symptoms, number of relapses, time delay in diagnosis, diagnostic methods, and treatment were obtained from clinical files. Infections, autoimmune diseases, and multiple sclerosis, among other conditions, were ruled out in all patients. RESULTS: We analyzed 30 patients with CRION: 24 women and six men, with mean age of 42.8±10.2 years, median disease course of 7.9 years (5.29-13.1), and median number of attacks of 2 (IQR 2-4). The initial manifestation was ocular pain in 97% and bilateral and sequential affection in 87%. Visual acuity was recovered in 50%, did not improve in 33%, and recovered incompletely in 17%. Antibodies against aquaporin-4 (AQP4-Abs) were negative in 73.3%. Magnetic resonance imaging of the brain was normal in 76.7%. None of the patients evolved to another demyelinating disease over time. Initial treatment was methylprednisolone in 100%, and plasmapheresis in 20%. Currently, all patients are on maintenance treatment with mycophenolate mofetil or rituximab with a decrease in relapsing rate. CONCLUSIONS: Diagnosis of CRION is challenging and should be kept in mind. Prompt diagnosis, adequate treatment and close follow-up are essential to prevent disabling sequelae in these patients.

[Rosai-Dorfman disease with spinal and cranial tumors. A clinical case reported]. / Enfermedad de Rosai-Dorfman y lesiones espinales y craneales. Informe de un caso clínico.

Rosai-Dorfman disease, known as well as sinus histiocytosis with massive lymphadenopathy, is a histiocytic proliferative disorder which may affect, with an extranodal presentation, the central nervous system, in 5 % of cases with exceptional reports of simultaneous development of spinal and cranial tumors. When it affects the central nervous system it appears more in men and it is shown as a mass in the cranial dura mater or in the spinal cord. The clinical symptoms of Rosai-Dorfman disease are fever, general malayse, weight loss, and nocturnal diaphoresis. Also, when Rosai-Dorfman disease affects the spinal cord, it has an impact on the thoracic spine, which causes paraparesis, quadriparesis, and sensory disorder. Histopathologically, the lymph nodes show emperipolesis. The diagnosis of Rosai-Dorfman disease is usually good, since 40 % of the patients present a spontaneous remission if they are treated with oral corticosteroids, even though the lesion can be managed with fractionated radiotherapy or with radical surgery. We report the case of a 34-year-old male who started with spinal injuries, and a year later showed intracranial lesions.

La enfermedad de Rosai-Dorfman, también conocida como histiocitosis sinusal con linfadenopatía masiva, es un trastorno histiocítico proliferativo que puede tener presentación extraganglionar a nivel del sistema nervioso central en 5 % de los casos, con reportes excepcionales de desarrollo de tumoraciones espinales y craneales de manera simultánea. Cuando afecta al sistema nervioso central tiene mayor presencia en los hombres y se manifiesta como una masa en la duramadre craneal o en la médula espinal. Fiebre, una sensación de malestar general, diaforesis nocturna y pérdida de peso son los síntomas clínicos de la enfermedad de Rosai-Dorfman. Asimismo, cuando esta afecta la médula espinal, la incidencia se da en la columna torácica, lo cual se manifiesta con paraparesia, cuadriparesia y trastornos sensoriales. Histopatológicamente, los ganglios linfáticos presentan linfofagocitosis o emperipolesis. El pronóstico de la enfermedad de Rosai-Dorfman suele ser bueno, pues 40 % de los pacientes experimenta una remisión espontánea al ser tratados con corticosteroides orales, si bien la enfermedad de Rosai-Dorfman también se puede manejar a largo plazo con dosis bajas de radioterapia fraccionada o, incluso, con una cirugía radical de la lesión. Se presenta el caso de un hombre de 34 años que inicia con lesiones espinales y un año después presentó lesiones intracraneales.

[Two cases of Dyke-Davidoff-Masson syndrome and adult cerebral hemiatrophy]. / Síndrome de Dyke-Davidoff-Masson y hemiatrofia cerebral del adulto. Informe de casos.

BACKGROUND: cerebral hemiatrophy (CHA) can present in childhood or adulthood, if it presents before or after two years of age. This two entities differ in etiology, clinical presentation and imaging characteristics. The CHA of childhood or Dyke-Davidoff-Masson syndrome, is originated by intrauterine or perinatal insults that affect the perfusion of a single cerebral hemisphere, manifesting clinically by variable mental retardation, refractory epilepsy, facial asymmetry, hemiplegia/hemiparesis or abnormal movements of the contralateral extremities and by imaging studies, loss of volume in one cerebral hemisphere and ipsilateral compensatory cranial changes such as skull vault thickening, elevation of the orbital roof and petreous ridge, also hyperpneumatization of the frontal sinus and mastoid cells. Instead, the CHA of the adult is multifactorial and by imaging it only manifests as loss of volume in one cerebral hemisphere, without compensatory changes in the skull. CASES REPORT: we present a classic clinical case of CHA secondary to perinatal insult and another case of CHA of adulthood secondary to multiple embolic strokes in a patient with inactive rheumatic heart disease, commenting the imaging differences of these rare clinical entities.

[Neurosarcoidosis. Report of one case in Mexico]. / Neurosarcoidosis. Informe de un caso un México.

INTRODUCTION: The sarcoidosis is a granulomatous, multisystemic disease, of unknown etiology that mainly affects the lungs, skin and lymphatic ganglia. The definitive diagnosis is made by the presence of granulomas non-caseous in diverse organs. Sarcoidosis is rare in Mexico and reports of its incidence do not exist. In Spain the incidence is low (1.2 to 1.5 cases by 100,000 inhabitants). In the United States incidence is 5.9 to 6.3 cases by 100,000 inhabitants (males and females respectively). Neurosarcoidosis is present in 5 to 26% of all the patients with sarcoidosis. The neurological manifestations are diverse, depending on the location site. CLINICAL CASE: We present the case of a male 33 years old, with recurrent facial paralysis, optic neuritis and affection of the third cranial nerve; the tomography of skull reveled an grow of left cavernous sinus and reinforcing bilateral temporal giral, and the nuclear magnetic resonance showed leptomeningeal reinforcing in the temporal lobe. CONCLUSION: Although the neurosarcoidosis is rare in Mexico, it should be considered in patients with suggestive clinical manifestations and compatible imaging findings. It should be done an intense search of systemic affection with biopsy and verification of non-caseous granulomas.